Phenotypes of Rapid Cystic Fibrosis Lung Disease Progression during Adolescence and Young Adulthood.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 28410569.
- Also identified by DOI 10.1164/rccm.201612-2574OC and PMC identifier 5564675.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Individuals with cystic fibrosis are at risk for prolonged drops in lung function, clinically termed rapid decline, during discreet periods of the disease. To identify phenotypes of rapid pulmonary decline and determine how these phenotypes are related to patient characteristics. A longitudinal cohort study of patients with cystic fibrosis aged 6-21 years was conducted using the Cystic Fibrosis Foundation Patient Registry. A statistical approach for clustering longitudinal profiles, sparse functional principal components analysis, was used to classify patients into distinct phenotypes by evaluating trajectories of FEV<sub>1</sub> decline. Phenotypes were compared with respect to baseline and mortality characteristics. Three distinct phenotypes of rapid decline were identified, corresponding to early, middle, and late timing of maximal FEV<sub>1</sub> loss, in the overall cohort (n = 18,387). The majority of variation (first functional principal component, 94%) among patient profiles was characterized by differences in mean longitudinal FEV<sub>1</sub> trajectories. Average degree of rapid decline was similar among phenotypes (roughly -3% predicted/yr); however, average timing differed, with early, middle, and late phenotypes experiencing rapid decline at 12.9, 16.3, and 18.5 years of age, respectively. Individuals with the late phenotype had the highest initial FEV<sub>1</sub> but experienced the greatest loss of lung function. The early phenotype was more likely to have respiratory infections and acute exacerbations at baseline or to develop them subsequently, compared with other phenotypes. By identifying phenotypes and associated risk factors, timing of interventions may be more precisely targeted for subgroups at highest risk of lung function loss.
Medical subject headings
- Cystic Fibrosis
- Disease Progression
- Lung